Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 8.01 (Other Events). EC approved new E4W (every-4-weeks) 2 mg/kg dosing regimen for Elfabrio in EU: expands label beyond prior dosing schedule.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- EC approved new E4W (every-4-weeks) 2 mg/kg dosing regimen for Elfabrio in EU: expands label beyond prior dosing schedule
- Label expansion targets stable Fabry disease patients on ERT, potentially broadening addressable patient pool and improving convenience vs. more frequent dosing
- Approval follows positive CHMP opinion from EMA: regulatory pathway was de-risked before EC decision
- Commercial partner Chiesi Global Rare Diseases handles EU commercialization, meaning PLX benefits via royalties/milestones rather than direct sales
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.